CLINICAL_TRIALS ClinicalTrials.gov record update

Effects of Dapagliflozin, an SGLT2 Inhibitor, on Hemodynamic Parameters, Target Organ Damage and Obesity Profile in Resistant Hypertensive Subjects

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03089333
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:56.309769+00:00
Published At: 2018-05-08T00:00:00+00:00
Record Updated At: 2018-05-08
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Hypertension", "Diabetes Mellitus, Type 2", "Blood Pressure", "Obesity", "Cardiac Hypertrophy", "Microalbuminuria", "Vascular Stiffness"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2018-05-08"
protocolSection.identificationModule.nctId: "NCT03089333"
protocolSection.identificationModule.officialTitle: "Effects of Dapagliflozin, an SGLT2 Inhibitor, on Hemodynamic Parameters, Target Organ Damage and Obesity Profile in Resistant Hypertensive Subjects"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE4"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.